Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Tolerability of Bifeprunox Re-initiation After Treatment Interruption
NCT00141479Phase 2Completed
- Sponsor
- Solvay
- Start
- May 2005
- Primary completion
- Nov 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of bifeprunox in schizophrenia and schizoaffective disorder, sponsored by Solvay. Primary endpoints: Safety and Tolerability of Bifeprunox Re-initiation and Safe Treatment Interruption Interval. Started May 2005; status: completed.
02
Drugs
bifeprunox
03
Conditions
schizophreniaschizoaffective disorder
Beyond the preview
Go deeper on NCT00141479.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00141479.